title: Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
abstract: Low-dose metronomic (LDM) chemotherapy represents an emerging concept in the treatment of cancer. Directed against tumor cells and other types of cells, such as endothelial and immune cells, this treatment regimen alters the tumor microenvironment and suppresses innate features which support tumor growth. Ongoing Phase III clinical studies explore various applications of LDM chemotherapy, mostly combined with other anticancer agents, to act as complementary treatments to conventional maximum tolerated dose (MTD) chemotherapy. In this article we summarize preclinical and clinical experience with LDM chemotherapy, emphasizing the potential contribution of this new treatment modality to future paradigms in the systemic treatment of patients with cancer.
authors.affiliation: Institute of Oncology, HaEmek Medical Center, Afula, Israel.
authors.forename: David
authors.initials: D
authors.lastname: Loven
authors.forename: Erez
authors.initials: E
authors.lastname: Hasnis
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertolini
authors.forename: Yuval
authors.initials: Y
authors.lastname: Shaked
mesh_terms: D059250:Administration, Metronomic; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D007107:Immune System / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents